RxCelerate took part in Rivus Pharmaceuticals’ $132m series B round while Bank of America and Citi backed AccessFintech’s $60m series C.

M&A Nasdaq-listed bladder cancer drug developer Sesen Bio has agreed to merge with Carisma Therapeutics, a US-based immunotherapy developer backed by pharmaceutical groups Penn Medicine, Merck & Co, Livzon Pharmaceutical and AbbVie. The combined business will receive $30m in financing from AbbVie, Penn Medicine, Merck’s MRL Ventures Fund, Livzon, HealthCap, Wellington Partners, SymBiosis, TPG Biotech,…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.